Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)
Year: 2007
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: S. Yazji, R. Bukowski, V. Kondagunta, R. Figlin
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2965751775